Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.1K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.0K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Adaptation of a Multidomain Behavioral Intervention for Dementia Prevention in Hispanic/Latino Adults: Protocol to Guide an Evidence-Based Cultural Adaptation.

Rhode Island medical journal (2013)·2026
Same author

Intismeran Autogene Plus Pembrolizumab Versus Pembrolizumab Alone in High-Risk Resected Melanoma: 5-Year Update of the Randomized Phase IIb KEYNOTE-942 Study.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Retrospective Study of Trametinib in Patients With Advanced <i>NF1</i>-Mutant Melanoma.

JCO precision oncology·2026
Same author

Correction: BRAF inhibitors suppress apoptosis through off-target inhibition of JNK signaling.

eLife·2026
Same author

Metastatic Uveal Melanoma Surveillance: A Delphi Panel Consensus.

Cancers·2026
Same author

Genomic copy-number variants drive apoptotic evasion underlying acquired resistance to immune checkpoint inhibitors.

Immunity·2025

Related Experiment Video

Updated: May 5, 2026

Analysis of Lymph Node Volume by Ultra-High-Frequency Ultrasound Imaging in the Braf/Pten Genetically Engineered Mouse Model of Melanoma
08:18

Analysis of Lymph Node Volume by Ultra-High-Frequency Ultrasound Imaging in the Braf/Pten Genetically Engineered Mouse Model of Melanoma

Published on: September 8, 2021

2.4K

Dabrafenib therapy for advanced melanoma.

Van Anh Trinh1, Jennifer E Davis, Jaime E Anderson

  • 1University of Texas MD Anderson Cancer Center, Houston, TX, USA.

The Annals of Pharmacotherapy
|November 22, 2013
PubMed
Summary

Dabrafenib is an effective BRAF inhibitor for advanced melanoma, showing similar efficacy to vemurafenib. Treatment selection may depend on individual tolerability and cost.

Keywords:
BRAF mutationGSK2118436advanced melanomadabrafenibselective BRAF inhibitorvemurafenib

More Related Videos

Screening for Melanoma Modifiers using a Zebrafish Autochthonous Tumor Model
10:23

Screening for Melanoma Modifiers using a Zebrafish Autochthonous Tumor Model

Published on: November 13, 2012

13.1K
Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells
06:09

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells

Published on: June 7, 2019

8.6K

Related Experiment Videos

Last Updated: May 5, 2026

Analysis of Lymph Node Volume by Ultra-High-Frequency Ultrasound Imaging in the Braf/Pten Genetically Engineered Mouse Model of Melanoma
08:18

Analysis of Lymph Node Volume by Ultra-High-Frequency Ultrasound Imaging in the Braf/Pten Genetically Engineered Mouse Model of Melanoma

Published on: September 8, 2021

2.4K
Screening for Melanoma Modifiers using a Zebrafish Autochthonous Tumor Model
10:23

Screening for Melanoma Modifiers using a Zebrafish Autochthonous Tumor Model

Published on: November 13, 2012

13.1K
Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells
06:09

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells

Published on: June 7, 2019

8.6K

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • The BRAF V600E mutation drives melanoma cell growth.
  • BRAF kinase inhibitors, such as dabrafenib and vemurafenib, target this mutation.
  • Dabrafenib has received approval for treating advanced BRAF V600E-positive melanoma.

Purpose of the Study:

  • To review the clinical development of dabrafenib.
  • To compare dabrafenib's distinct characteristics with vemurafenib.

Main Methods:

  • Literature search of MEDLINE/PubMed, meeting abstracts, and clinical registries (1966-June 2013).
  • Keywords included dabrafenib, vemurafenib, and BRAF inhibitors.
  • Review of published articles and ongoing study data.

Main Results:

  • Dabrafenib is approved for BRAF V600E-positive unresectable or metastatic melanoma.
  • It is safe and effective in patients with brain metastases.
  • Common side effects include hyperkeratosis, headache, pyrexia, and arthralgia.
  • No current evidence suggests one BRAF inhibitor is superior to another; selection may depend on tolerability and cost.

Conclusions:

  • Dabrafenib and vemurafenib confirm superior outcomes for BRAF inhibitors over dacarbazine in BRAF V600E-positive advanced melanoma.
  • Ongoing research aims to expand dabrafenib's use and overcome drug resistance.